prolactin

Appointment aligns Board leadership with Company’s transition to clinical-stage development and advancement of KAD-101 for platinum-resistant ovarian cancer Company advancing KAD-101, a best-in-class, next-generation prolactin receptor antagonist, toward a Phase 1 clinical study FORT LAUDERDALE, FL, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Kaida BioPharma (“Kaida” or the “Company”), Kaida BioPharma (“Kaida” or the “Company”), a biopharmaceutical company focused on advancing targeted anti-cancer therapies for hormone-driven cancers affecting women, today announced a leadership transition appointing Dr. Stella K. Vnook, Co-Founder of the Company, as Chairperson of the Board of Directors. This appointment reflects Kaida’s deliberate strategy to align Board leadership with the Company’s next phase of growth as it advances into clinical development. Since co-founding Kaida, Dr. Vnook has played a central role in shaping the Company’s scientific vision, strategic direction, and clinical, regulatory, and commercial roadmap, including the advancement of KAD-101, a best-in-class, next-generation prolactin receptor antagonist for the treatment of platinum-resistant ovarian cancer. Dr. Vnook’s appointment comes at a pivotal inflection point for Kaida as the Company prepares to enter the clinic with KAD-101—a novel therapeutic approach targeting a well-validated, hormone-driven survival pathway in ovarian cancer, a disease with limited treatment options and persistently poor outcomes. “The depth and breadth of Stella’s large-pharma and biotechnology experience, strategic insight, and global network will be integral to Kaida’s success,” said Craig Pierson, Founder and member of the Board of Directors. “Her leadership has been foundational to Kaida’s progress to date, and she is uniquely positioned to guide the Company through its transition into a clinical-stage organization as it advances into clinical development.” Dr. Vnook is an accomplished biotech founder, chief executive officer, and board advisor with more than 25 years of experience building, scaling, and transforming life sciences companies from inception through IPO or strategic exit. Throughout her career, Dr. Vnook has led multiple venture-backed biotechnology companies across oncology, cell and gene therapy, women’s health, neurology, and regenerative medicine. She has successfully secured institutional financing, expanded global intellectual property portfolios, formed strategic partnerships, and guided companies through IPOs and acquisitions. Her executive leadership experience includes senior roles at Enveric Biosciences, NAKI Therapeutics, MaiCell Therapeutics, Purdue Pharma, Catalent Pharma Solutions, and Merck & Co., where she contributed to the launch and commercialization of globally recognized pharmaceutical brands. “As a co-founder, I am deeply and personally committed to Kaida’s mission,” said Dr. Vnook. “This planned transition reflects the natural evolution of the Company as we advance into the clinic. I look forward to working closely with Craig, our Board, and the management team to build a company positioned for meaningful patient impact and long-term value creation in women’s health.” Dr. Vnook holds a Doctorate in Economics and Public Health, an MBA in Marketing, and a pharmacy degree with oncology residency training. She is known for her ability to translate innovative science into disciplined, value-creating enterprises that address significant unmet medical needs. At Kaida BioPharma, Dr. Vnook has played a foundational role in defining the Company’s women’s health strategy and advancing a pipeline designed to address large, underserved oncology markets with strong commercial potential. As Chairperson of the Board, she brings a rigorous, value-creation mindset to capital allocation, portfolio prioritization, and partnership strategy, informed by a track record of guiding companies through financings, IPOs, and strategic exits. Her leadership positions Kaida to efficiently advance its programs, attract high-quality investors and partners, and build a scalable platform focused on delivering differentiated therapies for women with cancer. About Kaida BioPharmaKaida BioPharma is a clinical-stage biopharmaceutical company developing targeted therapies for hormone-driven gynecologic cancers. The Company is founded on compelling clinical and translational evidence supporting the therapeutic benefit of disrupting the prolactin (PRL)–prolactin receptor (PRLR) signaling axis, a well-documented growth and survival pathway in ovarian and other gynecologic malignancies. Kaida’s lead product candidate, KAD-101, is a next-generation prolactin receptor antagonist designed to selectively and effectively block tumoral PRL/PRLR signaling, which has been shown in preclinical models to induce programmed cell death, including autophagy, in gynecologic tumors. The Company collaborates closely with leading academic investigators, including Dr. John Langenheim at Thomas Jefferson University and Dr. Anil Sood at MD Anderson Cancer Center, both of whom have published extensively on prolactin biology and its role in tumor growth, progression, and therapeutic resistance. Kaida is dedicated to delivering new hope for patients with treatment-resistant gynecologic cancers by developing innovative therapies that address critical unmet medical needs. For more information, please visit kaida-biopharma.com.Investor ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@jtcir.com

Report highlights emerging biotech innovators advancing new therapies, equity and investment across reproductive, chronic and mental health LONDON, Nov. 13, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its latest Companies to Watch report, Rediscovering Women's Health, highlighting seven companies driving innovation across reproductive care, chronic disease and mental health. Drawing on proprietary data, expert analysis and insights into therapeutic impact, financing activity and R&D momentum, the report showcases why these companies are recognized as high-impact innovators. Despite representing half the global population, women remain underrepresented in clinical research and healthcare investment, with women's health accounting for just 15% of venture capital and 5% of global healthcare R&D funding. Rediscovering Women's Health highlights organizations addressing these gaps through inclusive research, novel therapies and a deeper understanding of female-specific conditions such as early menopause, polycystic ovary syndrome (PCOS) and endometriosis, factors that influence broader outcomes like cardiovascular disease and dementia. The report also highlights growing momentum in women's health R&D. Anne Lecocq, SVP and GM, R&D, Life Sciences & Healthcare, Clarivate, said: "Women's health is no longer being defined solely by reproductive care; it's being reframed through a broader lens that recognizes how biological and social factors shape outcomes across every therapeutic area. This shift marks a pivotal moment for the industry, as data-driven innovation and inclusive research begin to translate into more equitable care and better health outcomes for women worldwide. By spotlighting organizations driving this change, the Companies to Watch report underscores how scientific insight and investment can work together to close persistent gaps and advance women's health globally." Agnès Arbat, MD, Co-Founder and CEO, Oxolife, said: "The next era of women's health innovation will be defined by science that recognizes women's unique biology as the foundation for discovery. Across the industry, we're seeing a long-overdue shift toward inclusive research and smarter, more targeted therapies that can truly transform outcomes for women." These companies are pioneering solutions that challenge outdated paradigms and promote equitable care. Clarivate analysts reviewed deal valuations, clinical trials, patents and market approvals to identify seven Companies to Watch in the space: Daré Bioscience (USA): focused on accelerating innovation in women's health by delivering evidence-based solutions that address long-standing unmet needs across contraception, sexual and vaginal health, pelvic pain, fertility, infectious disease and menopause. Freya™ Biosciences (Denmark/USA): leveraging its DYSCOVER™ multi-omics platform to develop microbial immunotherapies, including investigational vaginal therapy FB301, targeting chronic inflammation in female reproductive diseases and improving IVF outcomes. Gesynta Pharma (Sweden): developing treatments for chronic inflammation and pain, including lead candidate vipoglanstat, a non-hormonal, non-opioid, disease-modifying therapy for endometriosis. Granata Bio Corporation (USA): dedicated to advancing reproductive health by developing fertility treatments that expand options, improve access and affordability and drive innovation. Hope Medicine (Mainland China): developing therapies for endocrine, cardiovascular, and metabolic diseases, with a special focus on women's health, including lead asset HMI-115 targeting prolactin signaling to treat endometriosis, alopecia and related conditions. Oxolife (Spain): developing OXO-001 to improve fertility and live birth rates by enhancing embryo implantation, restoring ovulation, improving metabolic health and reducing pregnancy loss. Reunion Neurosciences (USA): developing psychedelic-inspired therapies, with lead candidate RE104 targeting postpartum depression and adjustment disorders to provide fast-acting benefits with limited psychoactive effects. Greater awareness, stronger regulatory frameworks supporting sexual health equity and increasing financial investment are accelerating progress in women's health. These developments create meaningful opportunities for the pharmaceutical industry to help close long-standing gaps and address unmet health needs for women worldwide. Learn more about emerging innovations and the seven companies shaping the future of women's health in the full Companies to Watch report, Rediscovering Women's Health, here. Methodology for the Companies to Watch Report Clarivate analysts employed a rigorous, multidimensional framework to identify the emerging innovators featured in this Companies to Watch report. Each company was assessed for its ability to address critical scientific, clinical and business challenges within the women's health space. Key considerations included demonstrated proof of concept, achievement of developmental milestones and positioning within the clinical trial landscape. The evaluation also factored in the strength of collaborations with leading academic and research institutions, the potential to address significant unmet medical needs and the overall burden of disease targeted by each therapy. Financial health was a further determinant, with analysts examining capital raised, investor partnerships, projected runway and prospects for future growth through fundraising or strategic alliances. Finally, each company's intellectual property estate was analyzed to understand the strength and breadth of its innovation pipeline. The assessment was underpinned by insights from Clarivate's trusted proprietary data sources, including Cortellis Competitive Intelligence, Cortellis Deals Intelligence, Cortellis Regulatory Intelligence, Cortellis Clinical Trials Intelligence and BioWorld, ensuring a holistic view of the companies poised to shape the future of precision oncology. About Clarivate Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com. Media Contact: Catherine Daniel Director, External Communications, Life Sciences & Healthcare [email protected] SOURCE Clarivate Plc 21% more press release views with Request a Demo

Dr. Erin Roe leads specialized evaluations and treatments to restore hormonal balance and improve quality of life. Our approach combines medical expertise with compassionate, individualized care so patients can feel confident in their path to recovery.” — Dr. Erin Roe DALLAS, TX, UNITED STATES, October 28, 2025 / EINPresswire.com / -- Sol Endocrinology , a premier endocrine clinic in Dallas led by board-certified endocrinologist Dr. Erin Roe, announces expanded diagnostic and treatment services for pituitary disorders , helping patients achieve hormonal balance through precision medicine and compassionate care. Often called the “master gland,” the pituitary gland orchestrates hormones that influence nearly every aspect of health, from metabolism and growth to mood and reproductive function. When the pituitary gland malfunctions, even slightly, the effects can ripple throughout the entire body. Recognizing the importance of early diagnosis and expert management, Dr. Roe and her team at Sol Endocrinology provide advanced, personalized care for a range of pituitary-related conditions. “The pituitary gland plays an extraordinary role in regulating overall health, yet disorders affecting it are often misunderstood or overlooked,” said Dr. Erin Roe, founder of Sol Endocrinology. “Our goal is to bring clarity and care to patients experiencing these complex hormonal imbalances, helping them understand their symptoms and guiding them toward lasting wellness.” Expertise in Diagnosing Complex Pituitary Conditions Sol Endocrinology offers thorough evaluations for conditions such as: - High Prolactin Levels (Hyperprolactinemia): Elevated prolactin can cause irregular menstrual cycles, infertility, and galactorrhea. Dr. Roe utilizes advanced diagnostic testing to determine the root cause, such as a prolactinoma, and provides targeted medical therapies to restore hormonal balance. - Abnormal Breast Discharge (Galactorrhea): This symptom, present in both men and women, can indicate pituitary dysfunction. Comprehensive hormone assessments guide customized treatment plans. - Pituitary Adenomas: Noncancerous tumors that can alter hormone production, leading to headaches, vision changes, fatigue, and weight fluctuations. Sol Endocrinology coordinates comprehensive management, including medical therapy, surgical referrals, and ongoing monitoring. Comprehensive Diagnostic Approach Each evaluation begins with a detailed clinical assessment led by Dr. Roe, who examines medical history, symptoms, and physical signs of hormonal imbalance. Diagnostic imaging, such as Magnetic Resonance Imaging (MRI), provides high-resolution visualization of the pituitary gland and surrounding structures, while blood testing and visual field exams further clarify functional changes. This meticulous process allows for accurate diagnosis and the creation of personalized treatment plans that address each patient’s unique endocrine profile. Innovative and Individualized Treatment Options Sol Endocrinology emphasizes individualized therapy for pituitary disorders. Treatment options include: - Medication Management: Dopamine agonists and other targeted medications help normalize hormone levels and, in some cases, shrink pituitary tumors. - Hormone Replacement Therapy: Restores optimal function for patients with pituitary insufficiencies. - Radiation Therapy: For patients unable to undergo surgery or for residual tumors unresponsive to medication, targeted radiation provides an effective alternative with close post-treatment monitoring. Empowering Patients Through Education Because pituitary disorders often present with subtle or overlapping symptoms, such as fatigue, headaches, vision changes, or unexplained weight fluctuations, early recognition is vital. Sol Endocrinology prioritizes patient education to promote awareness and proactive health management. “Empowering patients to understand their symptoms and seek timely evaluation can change outcomes dramatically,” said Dr. Roe. “Our approach combines medical expertise with compassionate, individualized care so patients can feel confident in their path to recovery.” About Sol Endocrinology Located in the heart of Dallas, Sol Endocrinology offers comprehensive endocrine care across conditions affecting the thyroid, adrenal glands, metabolism, reproductive hormones, and bone health. Under Dr. Roe’s leadership, the clinic combines clinical precision, cutting-edge diagnostic tools, and a patient-first philosophy to help individuals regain control of their health and vitality. Dr. Erin Roe Sol Endocrinology +1 469-648-3636 email us here Visit us on social media: Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.